Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26326285 | 0.89 | NPC1 (0.37) | MAPTPOLBNPC1VCAM1L3MBTL1 | |
| SCHEMBL26326258 | 0.84 | MAPT (0.37) | MAPTPOLBL3MBTL1LMNAKDM4E | |
| SCHEMBL26083445 | 0.82 | NPC1 (0.39) | MAPTPOLBNPC1VCAM1L3MBTL1 | |
| SCHEMBL26326295 | 0.80 | NPC1 (0.40) | MAPTPOLBNPC1VCAM1L3MBTL1 | |
| SCHEMBL25475020 | 0.76 | GAA (0.40) | MAPTPOLBL3MBTL1LMNAHTT | |
| SCHEMBL26326300 | 0.70 | MAPT (0.43) | MAPTPOLBNPC1VCAM1LMNA | |
| SCHEMBL25474987 | 0.69 | NPC1 (0.35) | MAPTPOLBNPC1VCAM1L3MBTL1 | |
| SCHEMBL26326280 | 0.68 | HPGD (0.34) | MAPTPOLBLMNAHTTKMT2A | |
| SCHEMBL24165289 | 0.67 | PTGDR2 (0.36) | MAPTPOLBNPC1LMNAHTT | |
| SCHEMBL30846791 | 0.66 | LMNA (0.37) | MAPTPOLBNPC1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | MAPT 4580/4885POLB 828/4885NPC1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.